New drug cocktail targets Hard-to-Treat myeloma
NCT ID NCT06876142
First seen Jun 27, 2026 · Last updated Jul 01, 2026 · Updated 3 times
Summary
This study tests two oral drugs, mirdametinib and sirolimus, in people with relapsed or refractory multiple myeloma that has specific RAS gene mutations. The trial has two phases: first to find a safe dose, then to see how well the combo works. Up to 54 adults will take the drugs daily in 4-week cycles for a year, with follow-up for 4 more years. The study is currently suspended.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Mirdametinib and sirolimus
What this could lead to
If it works, this could offer a new treatment option for people with multiple myeloma that has not responded to other therapies and has specific gene changes.
What could go wrong
This is an early-phase trial (1b/2) with only 54 participants, currently suspended. The combination may cause side effects or fail to show benefit. Results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States